Orion pharmaceutical research earmarked for EIB money

Published: 14-Aug-2009
Research & Development

EIB to lend Orion Euro 75m to help pharmaceutical research and development work


The European Investment Bank (EIB) is planning to lend Finland's Orion Euro 75m to help it stage pharmaceutical research and development work from this year to 2012.

Part of a â"šÂ¬300m programme, the work would be carried out within Orion's existing r&d facilities, laboratories, pilot plants and clinical centres.

  • Companies:
  • Orion Group
See more

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Read more
Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)

Trending Articles

  1. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation
  2. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  3. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  4. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

Orion Corporation and Glykos Finland Oy have entered into a research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs)
Research & Development

Orion and MSD announce two Phase III trials to evaluate ODM-208/MK5684 in patients with metastatic castration-resistant prostate cancer

OMAHA1 and OMAHA2a are the first Phase III trials to be initiated for ODM-208/MK5684
Research & Development

Orion and MSD announce global collaboration to develop and commercialise ODM-208

Agreement strengthens and complements MSD’s oncology pipeline
Drug Delivery

Nanoform and Orion collaborate on next-generation drug development

This collaboration will utilise Nanoform’s proprietary CESS technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development
Research & Development

In the pursuit of new medicines for oncological diseases

The Wisconsin Technology Innovation Initiative (Wi2) and Orion Corporation have announced a new strategic collaboration
Research & Development

Endo and Orion agree collaboration deal

Will bring forward eight drug candidates and share development costs
Drug Delivery

DelSiTech in research collaboration with Orion

Sign agreement that will enable Orion to apply DelSiTech proprietary drug delivery technology
Subscribe now